financetom
Business
financetom
/
Business
/
GXO Logistics' Wincanton Acquisition Placed Under In-Depth Probe by UK Regulator
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GXO Logistics' Wincanton Acquisition Placed Under In-Depth Probe by UK Regulator
Nov 15, 2024 12:24 AM

08:37 AM EST, 11/14/2024 (MT Newswires) -- GXO Logistics' ( GXO ) completed acquisition of Wincanton was referred by the Competition and Markets Authority for an in-depth investigation, the UK regulator said Thursday.

The regulator said it made the referral because "it is or may be the case that this merger may be expected to result in a substantial lessening of competition" in the UK.

GXO closed its acquisition of Wincanton in April.

GXO didn't immediately respond to a request for comment from MT Newswires.

Price: 58.50, Change: -0.08, Percent Change: -0.14

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alvotech H1 Loss Widens, Revenue Increases; Full-Year Guidance Reaffirmed
Alvotech H1 Loss Widens, Revenue Increases; Full-Year Guidance Reaffirmed
Aug 15, 2024
04:56 PM EDT, 08/15/2024 (MT Newswires) -- Alvotech ( ALVO ) reported an H1 loss late Thursday of $0.61 per diluted share, widening from a loss of $0.39 a year earlier. Revenue for the six months ended June 30 was about $235.6 million, compared with $20.3 million a year earlier. Analysts' estimates were unavailable for comparison. Alvotech ( ALVO )...
Incyte Cancer Treatment Candidate Meets Primary Goal in Study
Incyte Cancer Treatment Candidate Meets Primary Goal in Study
Aug 15, 2024
04:55 PM EDT, 08/15/2024 (MT Newswires) -- Incyte ( INCY ) said Thursday that its cancer drug Monjuvi met the primary goal of phase 3 study by showing progression-free survival in patients with relapsed or refractory follicular lymphoma. Incyte ( INCY ) was evaluating Monjuvi, or tafasitamab, in combination with lenalidomide and rituximab in the study, according to the company....
Atlassian Insider Sold Shares Worth $1,141,067, According to a Recent SEC Filing
Atlassian Insider Sold Shares Worth $1,141,067, According to a Recent SEC Filing
Aug 15, 2024
04:54 PM EDT, 08/15/2024 (MT Newswires) -- Scott Farquhar, 10% Owner, Director, Co-CEO, Co-Founder, on August 14, 2024, sold 7,948 shares in Atlassian ( TEAM ) for $1,141,067. Following the Form 4 filing with the SEC, Farquhar has control over a total of 254,336 shares of the company, with 254,336 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218024006287/xslF345X03/primarydocument.xml Price: 146.00, Change: -0.83, Percent...
Parker Hannifin Insider Sold Shares Worth $1,043,369, According to a Recent SEC Filing
Parker Hannifin Insider Sold Shares Worth $1,043,369, According to a Recent SEC Filing
Aug 15, 2024
04:54 PM EDT, 08/15/2024 (MT Newswires) -- Rachid Bendali, Vice President and President, Engineered Materials Group, on August 13, 2024, sold 1,815 shares in Parker Hannifin ( PH ) for $1,043,369. Following the Form 4 filing with the SEC, Bendali has control over a total of 2,276 shares of the company, with 2,234 shares held directly and 42 controlled indirectly....
Copyright 2023-2026 - www.financetom.com All Rights Reserved